 PARIS and CAMBRIDGE, Mass., July 12, 2021 GLOBE NEWSWIRE -- Biophytis SA Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the company, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19 today announces new positive preclinical data on Sarconeos BIO101 in hamsters infected with SARS-CoV-2. 